Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISA-T2DM: Acarbose vs Vildagliptin on Visceral Fat in Newly Diagnosed T2DM
NCT02999841Phase 4Unknown
- Sponsor
- Peking University
- Start
- Mar 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of acarbose in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Peking University. Primary endpoint: Change of the visceral fat area at 24 weeks. Status: unknown.
02
Drugs
acarbose
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT02999841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02999841.